


PDA Survey



Risk Mitigation of Tribromoanisole (TBA)/Trichloroanisole (TCA) Taints and Odors: A Pharmaceutical Industry Benchmarking Survey



Parenteral Drug Association

Connecting People, Science and Regulation®

PDA Survey

Risk Mitigation of Tribromoanisole (TBA)/ Trichloroanisole (TCA) Taints and Odors: A Pharmaceutical Industry Benchmarking Survey

ISBN: 978-0-939459-37-7

© 2011 Parenteral Drug Association, Inc.

All rights reserved.



PDA Tribromoanisole (TBA)/Trichloroanisole (TCA) Task Force

Anil Sawant, Ph.D., (Chair), Johnson & Johnson

William Beierschmitt, Ph.D., Pfizer Inc.

Jeff Burris

William Callahan, Ph.D., DepoMed

John Clark, MD, MSPH Risk Benefits, LLC

Anthony Cundell, Ph.D., Merck & Co.

Michael Fairbanks, Perrigo

Jonine Greyling, Ph.D., Johnson & Johnson

Rachel Humphreys, Mylan

Nirdosh Jagota, Ph.D., Genentech, a Member of the Roche Group

Robert Johnson

Douglas Knawby, Ph.D., Johnson & Johnson

Rich Levy, Ph.D., PDA

Janet Lim, MD, Johnson & Johnson

Wendy Luo, Ph.D., Bristol-Myers Squibb Company

William Powers, Ph.D., Johnson & Johnson

Gustavo S. Rodriguez, Rexam Healthcare

Doug Ross, MD, Pfizer Inc.

Sarah Sellers

Edward J. Smith, Ph.D., Packaging Science Resources

Megan Sewell, Merck & Co.

Katherine Stetson, GlaxoSmithKline

Dirk E. Stevens, Ph.D., Covidien Pharmaceuticals

James Strickland, Pfizer Inc.

Eric Thostesen, Janssen Pharmaceutical Company

Annalisa Torrente, Project Manager

David A. Ulrich, Abbott Laboratories

Christine Vietri, AstraZeneca Pharmaceuticals

Gary E. Wilson, West Pharmaceuticals Services, Inc.

Table of Contents

INTRODUCTION	1
1. COMPLAINTS HANDLING SYSTEM (QUESTIONS 1-7)	2
2. SUPPLY CHAIN CONTROLS (QUESTIONS 8-26)	4
3. ANALYTICAL METHODS (QUESTIONS 27-30)	10
4. REGULATORY FOCUS (QUESTIONS 31-32)	11
5. CONCLUSIONS	12